BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dal Monte M, Cammalleri M, Pecci V, Carmosino M, Procino G, Pini A, De Rosa M, Pavone V, Svelto M, Bagnoli P. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. J Cell Mol Med 2019;23:1034-49. [PMID: 30426662 DOI: 10.1111/jcmm.14004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Benchoula K, Parhar IS, Madhavan P, Hwa WE. CREB nuclear transcription activity as a targeting factor in the treatment of diabetes and diabetes complications. Biochem Pharmacol 2021;188:114531. [PMID: 33773975 DOI: 10.1016/j.bcp.2021.114531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kim EY, Dryer SE. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes. Biochim Biophys Acta Mol Basis Dis 2021;1867:166186. [PMID: 34166766 DOI: 10.1016/j.bbadis.2021.166186] [Reference Citation Analysis]
3 Cassis P, Zoja C, Perico L, Remuzzi G. A preclinical overview of emerging therapeutic targets for glomerular diseases. Expert Opin Ther Targets 2019;23:593-606. [PMID: 31150308 DOI: 10.1080/14728222.2019.1626827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
4 Li M, Liu X, Zhang Z. Hyperglycemia exacerbates cadmium-induced glomerular nephrosis. Toxicol Ind Health 2021;37:555-63. [PMID: 34452584 DOI: 10.1177/07482337211037880] [Reference Citation Analysis]
5 Raval N, Jogi H, Gondaliya P, Kalia K, Tekade RK. Cyclo-RGD Truncated Polymeric Nanoconstruct with Dendrimeric Templates for Targeted HDAC4 Gene Silencing in a Diabetic Nephropathy Mouse Model. Mol Pharm 2021;18:641-66. [PMID: 32453574 DOI: 10.1021/acs.molpharmaceut.0c00094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS; International Study of Inflammation in COVID-19. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. J Am Soc Nephrol 2020;31:2725-35. [PMID: 32963090 DOI: 10.1681/ASN.2020060829] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
7 Yuan C, Guo Z, Yu S, Jiang L, Huang M. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. Drug Discov Today 2021;26:1076-85. [PMID: 33486111 DOI: 10.1016/j.drudis.2021.01.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Cammalleri M, Dal Monte M, Locri F, Pecci V, De Rosa M, Pavone V, Bagnoli P. The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model. J Cell Mol Med 2019;23:5176-92. [PMID: 31251468 DOI: 10.1111/jcmm.14391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
9 Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, Sever S, Camacho A, Wang X, Dande RR, Ibrahim NE, Baron RM, Altintas MM, Wei C, Sheikh-Hamad D, Pan JS, Holliday MW Jr, Januzzi JL, Weisbord SD, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med 2020;382:416-26. [PMID: 31995687 DOI: 10.1056/NEJMoa1911481] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 27.0] [Reference Citation Analysis]
10 D'Alonzo D, De Fenza M, Pavone V. COVID-19 and pneumonia: a role for the uPA/uPAR system. Drug Discov Today 2020;25:1528-34. [PMID: 32562843 DOI: 10.1016/j.drudis.2020.06.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
11 Cammalleri M, Dal Monte M, Pavone V, De Rosa M, Rusciano D, Bagnoli P. The uPAR System as a Potential Therapeutic Target in the Diseased Eye. Cells 2019;8:E925. [PMID: 31426601 DOI: 10.3390/cells8080925] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. BMC Nephrol 2018;19:361. [PMID: 30558559 DOI: 10.1186/s12882-018-1177-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Dal Monte M, Cammalleri M, Pecci V, Carmosino M, Procino G, Pini A, De Rosa M, Pavone V, Svelto M, Bagnoli P. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. J Cell Mol Med 2019;23:1034-49. [PMID: 30426662 DOI: 10.1111/jcmm.14004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]